Voyager Therapeutics (VYGR) Change in Receivables (2019 - 2026)

Voyager Therapeutics has disclosed Change in Receivables across 5 years of filings, most recently posting -$267000.0 for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$267000.0, down 324.37% year-over-year; the trailing twelve-month figure through Mar 2026 was -$129000.0 (down 116.41% YoY), and the FY2025 annual result was $257000.0, up 100.33% from the prior year.
• Change in Receivables came in at -$267000.0 for Q1 2026 at Voyager Therapeutics, up from -$1.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $25.0 million in Q1 2023 to a low of -$79.3 million in Q1 2024.
• The 4-year median for Change in Receivables is $85000.0 (2025), against an average of -$5.4 million.
• Across the five-year window, Change in Receivables plunged 417.25% in 2024 and soared 100.15% in 2025, its largest moves.
• Voyager Therapeutics' Change in Receivables stood at $25.0 million in 2023, then plunged by 157.8% to -$14.4 million in 2024, then jumped by 90.14% to -$1.4 million in 2025, then jumped by 81.26% to -$267000.0 in 2026.
• The last three Change in Receivables figures came in at -$267000.0 (Q1 2026), -$1.4 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.